Visceral Leishmaniasis Treatment, Italy

First-line drug treatment was recorded in 573 immunocompetent patients with visceral leishmaniasis in Italy. In the past 12 years, the proportion of antimonial treatments decreased from 100% to 2.8%, while the proportion of amphotericin B treatments increased from 0% to 97.2%. The countrywide change...

Descripción completa

Detalles Bibliográficos
Autores principales: Gradoni, Luigi, Gramiccia, Marina, Scalone, Aldo
Formato: Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2003
Materias:
Dispatch
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3034325/
https://www.ncbi.nlm.nih.gov/pubmed/14720406
http://dx.doi.org/10.3201/eid0912.030178
Descripción
Sumario:First-line drug treatment was recorded in 573 immunocompetent patients with visceral leishmaniasis in Italy. In the past 12 years, the proportion of antimonial treatments decreased from 100% to 2.8%, while the proportion of amphotericin B treatments increased from 0% to 97.2%. The countrywide change in therapy is a response to both disease reemergence and increasing antimonial failure.

Ejemplares similares